Evidence map›Paper›PMID 31594101›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2019

[Effect of antiviral therapy on the occurrence of hepatitis B-related hepatocellular carcinoma].

J Sun, S Zhang, Y X Wang, L Zhu, H C Xing

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J SunDepartment of Hepatology, Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
S Zhang
Y X Wang
L Zhu
H C Xing
Beijing Ditan Hospital · CN

Funding

Beijing Hospital Administration Department of Gastroenterology Collaborative Development Center Project XXT26Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support XMLX201837Capital Health Development Research Project first 2018-2-2173National Science and Technology Major Project of China Under Gran 2018ZX10302206-003-006Wu Jieping Medical Foundation LDWJPMF-103-17001
6 · The paper itself

Abstract

Clinically, hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high rate of morbidity and mortality. Hepatitis B virus infection is the main cause of hepatocellular carcinoma in China and it is a serious threat to people's health. Antiviral drugs such as nucleos(t)ide analogues and interferon can inhibit viral replication and liver fibrosis progression and reduce the occurrence of hepatitis B-related HCC. This article reviews the effects of different antiviral therapy on the occurrence of hepatitis B-related hepatocellular carcinoma in recent years.

Indexed as

Antiviral AgentsCarcinoma, HepatocellularChinaHepatitis BHepatitis B virusHumansLiver CirrhosisLiver NeoplasmsAntiviral AgentsHepatitis B virusHepatocellular carcinomaInterferonNucleotide analogues

Identifiers

PMID31594101
PMCPMC12770165
OpenAlexW2984311112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.